Nxera seeks schizophrenia programme buyer after Boehringer snub
December 22, 2025
Source: drugdu
32
Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a licensing option.
Boehringer Ingelheim, which held exclusive rights to license the neurological disorder portfolio of GPR52 agonists, did not provide further information to Nxera. Rights to the programme will now revert to the Japanese biotech.
Nxera said it is now exploring strategic opportunities for the programme, including a licensing partnership with a major pharmaceutical or specialist neuroscience company in 2026. Despite the hitch, Nxera said there will be no financial impact.
https://www.pharmaceutical-technology.com/news/nxera-seeks-schizophrenia-programme-buyer-after-boehringer-snub/
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- First innovative traditional Chinese medicine for frequent tension headaches launched. December 22, 2025
- The battle for rivaroxaban intensifies! Guilin Pharmaceutical enters the fray with its first generic dry suspension December 22, 2025
- Another biotech company goes bankrupt December 22, 2025
- Phase III Clinical Trial of Innovative Prostate Cancer Diagnostic Radiopharmaceutical TLX591-CDx Reaches Primary Endpoint in China December 22, 2025
- First Subject Dosed in Phase I Multiple Ascending Dose (MAD) Study of LAE102 for the Treatment of Obesity December 22, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
